Should I buy or sell Gritstone bio stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GRTS shares. View GRTS analyst ratings or view top-rated stocks .

What is Gritstone bio's stock price target for 2024?

4 brokerages have issued 12-month target prices for Gritstone bio's stock. Their GRTS share price targets range from $7.00 to $8.00. On average, they anticipate the company's stock price to reach $7.33 in the next year. This suggests a possible upside of 259.5% from the stock's current price. View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts .

How have GRTS shares performed in 2023?

Gritstone bio's stock was trading at $3.45 at the start of the year. Since then, GRTS stock has decreased by 40.9% and is now trading at $2.04. View the best growth stocks for 2023 here .

When is Gritstone bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our GRTS earnings forecast .

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) issued its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. The company had revenue of $1.57 million for the quarter, compared to analyst estimates of $2.10 million. Gritstone bio had a negative trailing twelve-month return on equity of 112.25% and a negative net margin of 1,359.04%.

What ETF holds Gritstone bio's stock ?

Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio.

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com . Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Matinas BioPharma (MTNB) , Novan (NOVN) , Sorrento Therapeutics (SRNE) , Zosano Pharma (ZSAN) , Enerplus (ERF) , Oncolytics Biotech (ONCY) , SCYNEXIS (SCYX) and CBL & Associates Properties (CBL) .

When did Gritstone bio IPO?

(GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Gritstone bio?

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

$2.04

-0.02 (-0.97%)

(As of 12/29/2023 ET)

Compare

Today's Range: $1.95
▼
$2.07
50-Day Range: $1.28
▼
$2.10
52-Week Range: $1.14
▼
$3.86

Volume: 930,366 shs
Average Volume: 1.49 million shs
Market Capitalization: $194.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.33

Gritstone bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 259.5% Upside
$7.33 Price Target
Short Interest: Healthy
9.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.30) to ($1.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

414th out of 950 stocks

Biological Products, Except Diagnostic Industry

76th out of 158 stocks

3.5

Analyst's Opinion

Consensus Rating
Gritstone bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.33, Gritstone bio has a forecasted upside of 259.5% from its current price of $2.04.
Amount of Analyst Coverage
Gritstone bio has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
9.92% of the float of Gritstone bio has been sold short.
Short Interest Ratio / Days to Cover
Gritstone bio has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Gritstone bio has recently decreased by 4.50%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Gritstone bio does not currently pay a dividend.
Dividend Growth
Gritstone bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GRTS.

2.7

News and Social Media Coverage

News Sentiment
Gritstone bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Gritstone bio this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for GRTS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
4 people have added Gritstone bio to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gritstone bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.61% of the stock of Gritstone bio is held by insiders.
Percentage Held by Institutions
54.79% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Gritstone bio are expected to grow in the coming year, from ($1.30) to ($1.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gritstone bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gritstone bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gritstone bio has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gritstone bio Stock (NASDAQ:GRTS)

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

GRTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GRTS Stock News Headlines

December 29, 2023 | benzinga.com

Gritstone Bio Stock (NASDAQ:GRTS) Dividends: History, Yield and Dates

December 22, 2023 | msn.com

Gritstone bio files for a $250M mixed securities shelf

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 13, 2023 | finance.yahoo.com

Forecast: Analysts Think Gritstone bio, Inc.'s (NASDAQ:GRTS) Business Prospects Have Improved Drastically

November 8, 2023 | finance.yahoo.com

Gritstone Bio Inc (GRTS) Reports Q3 2023 Financial Results and Progress in Vaccine Development

November 8, 2023 | finance.yahoo.com

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

October 16, 2023 | msn.com

Gritstone bio Inc. (GRTS) Upgraded to Buy: What Does It Mean for the Stock?

October 14, 2023 | msn.com

Gritstone bio: Renewed Excitement For Its COVID-19 Vaccine

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

October 12, 2023 | benzinga.com

Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio's BARDA Award

October 12, 2023 | finance.yahoo.com

Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award

October 11, 2023 | finance.yahoo.com

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine

October 7, 2023 | msn.com

Jones starts Gritstone at buy; cites cancer, COVID-19 vaccines

October 5, 2023 | msn.com

Gritstone Bio (GRTS) Price Target Increased by 22.09% to 10.71

October 5, 2023 | finance.yahoo.com

retail investors who own 43% along with institutions invested in Gritstone bio, Inc. (NASDAQ:GRTS) saw increase in their holdings value last week

October 4, 2023 | finance.yahoo.com

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

September 30, 2023 | msn.com

Piper Sandler Maintains Gritstone Bio (GRTS) Overweight Recommendation

September 28, 2023 | marketwatch.com

Gritstone Bio Shares Rise 17% After Contract to Study Covid-19 Vaccine Candidate

September 28, 2023 | msn.com

Gritstone shares rally on BARDA contract for new COVID-19 vaccine

September 28, 2023 | markets.businessinsider.com

Gritstone Bio Gets BARDA Contract To Study COVID-19 Vaccine Candidate Worth Up To $433 Mln

September 28, 2023 | msn.com

Why Is Vaccine Focused Gritstone bio Stock Trading Higher Today?

September 27, 2023 | finance.yahoo.com

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

August 15, 2023 | finance.yahoo.com

Gritstone bio and Genevant Sciences Announce Option and License Agreement

August 14, 2023 | finance.yahoo.com

What Does The Future Hold For Gritstone bio, Inc. (NASDAQ:GRTS)? These Analysts Have Been Cutting Their Estimates

August 9, 2023 | finance.yahoo.com

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

August 7, 2023 | finance.yahoo.com

Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project

August 1, 2023 | msn.com

Gritstone: Trying To Pick Itself Up From The COVID Ruins

See More Headlines

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GRTS
CUSIP: N/A
CIK: 1656634
Web: www.gritstoneoncology.com
Phone: (510) 871-6100
Fax: N/A
Employees: 233
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.33
High Stock Price Target: $8.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +259.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,690,000.00
Net Margins: -1,359.04%
Pretax Margin: -1,359.04%
Return on Equity: -112.25%
Return on Assets: -64.59%

Debt

Debt-to-Equity Ratio: 0.40
Current Ratio: 3.88
Quick Ratio: 3.88

Sales & Book Value

Annual Sales: $19.94 million
Price / Sales: 9.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.05 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 95,340,000
Free Float: 90,947,000
Market Cap: $194.49 million
Optionable: Not Optionable
Beta: 0.42

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Andrew R. Allen BCh (Age 56)
BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director
Comp: $983.44k
Mr. Erin E. Jones M.S. (Age 51)
Executive VP & COO
Comp: $658.01k
Dr. Karin Jooss Ph.D. (Age 58)
Executive VP and Head of Research & Development
Comp: $706.07k
Ms. Vassiliki Economides (Age 42)
Executive VP & CFO
Mr. James Cho
Chief Accounting Officer
George MacDougall
Director of Investor Relations & Corporate Communications
Ms. Stacy Proctor
Executive VP & Chief People Officer
Dr. Matthew J. Hawryluk M.B.A. (Age 45)
Ph.D., Executive VP & Chief Business Officer
Mr. Vijay Yabannavar Ph.D. (Age 61)
Executive VP & Chief Technical Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GRTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gritstone bio stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GRTS shares.
View GRTS analyst ratings or view top-rated stocks.
What is Gritstone bio's stock price target for 2024?: 4 brokerages have issued 12-month target prices for Gritstone bio's stock. Their GRTS share price targets range from $7.00 to $8.00. On average, they anticipate the company's stock price to reach $7.33 in the next year. This suggests a possible upside of 259.5% from the stock's current price.
View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts.
How have GRTS shares performed in 2023?: Gritstone bio's stock was trading at $3.45 at the start of the year. Since then, GRTS stock has decreased by 40.9% and is now trading at $2.04.
View the best growth stocks for 2023 here.
When is Gritstone bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our GRTS earnings forecast.
How were Gritstone bio's earnings last quarter?: Gritstone bio, Inc. (NASDAQ:GRTS) issued its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. The company had revenue of $1.57 million for the quarter, compared to analyst estimates of $2.10 million. Gritstone bio had a negative trailing twelve-month return on equity of 112.25% and a negative net margin of 1,359.04%.
What ETF holds Gritstone bio's stock ?: Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio.

What is Andrew Allen's approval rating as Gritstone bio's CEO?: 1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Gritstone bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).
When did Gritstone bio IPO?: (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Gritstone bio?: Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRTS) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial